Emerging viral infections, such as Parvovirus B19, have been associated with autoimmune conditions like rheumatoid arthritis (RA). Effective diagnostics are essential for identifying these viral triggers, yet challenges remain in achieving high accuracy across diverse clinical settings. This study evaluates the diagnostic performance of two Parvovirus B19 ELISA kits—MyBiosource and Diasorin Liaison—in the detection of anti-Parvovirus B19 IgM and IgG antibodies in autoimmune disease patients.

 We conducted a comparative analysis, assessing key performance metrics including sensitivity, specificity, assay time, automation compatibility, and intra-assay variability. The MyBiosource ELISA Kit demonstrated 99% sensitivity and specificity with a manual sandwich ELISA format, while the Diasorin Liaison Kit achieved 100% sensitivity and 99.56% specificity through an automated chemiluminescence immunoassay compatible with the LIAISON XL Analyzer. Sample types and preparation protocols were also compared, revealing nuanced differences in handling requirements that influence diagnostic applicability in high-throughput settings.

 Preliminary results indicate that both kits offer reliable performance, though the automated Diasorin Liaison kit may better support large-scale screening due to reduced assay time and enhanced standardization. This study underscores the importance of selecting appropriate diagnostic tools in identifying viral triggers of autoimmune conditions and highlights the potential for automation in advancing infectious disease research.

Yousra Abdelmoumen is a dedicated PhD student specializing in clinical immunology, inflammation, and allergy at the esteemed Medical and Pharmacy Faculty of Casablanca, Morocco. With a keen interest in Parvovirus B19 infection, she delves into its manifestations in both adults and children. Yousra's research sheds light on the varied clinical presentations of Parvovirus B19, from childhood erythema infectiosum to arthropathy and hematologic disorders in adults. She participated in numerous oral presentations on Parvovirus B19. Notably at the African Society of Immunodeficiency International Congress in 2023 and The international Parvovirus Workshop in Leuven, Belgium September 2024, sparking meaningful discussions among experts.